ES2145286T3 - Uso de un antagonista gnrh para la preparacion de una composicion farmaceutica. - Google Patents

Uso de un antagonista gnrh para la preparacion de una composicion farmaceutica.

Info

Publication number
ES2145286T3
ES2145286T3 ES95927228T ES95927228T ES2145286T3 ES 2145286 T3 ES2145286 T3 ES 2145286T3 ES 95927228 T ES95927228 T ES 95927228T ES 95927228 T ES95927228 T ES 95927228T ES 2145286 T3 ES2145286 T3 ES 2145286T3
Authority
ES
Spain
Prior art keywords
gnrh
antagonist
dose
southern
gonadal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95927228T
Other languages
English (en)
Inventor
Gary D Hodgen
Audrey Philips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Medical College of Hampton Roads
Original Assignee
Ortho Pharmaceutical Corp
Medical College of Hampton Roads
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2145286(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by Ortho Pharmaceutical Corp, Medical College of Hampton Roads filed Critical Ortho Pharmaceutical Corp
Application granted granted Critical
Publication of ES2145286T3 publication Critical patent/ES2145286T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REGIMEN PARA EL CONTROL TERAPEUTICO DE UNA AFECCION DE CAUSA GONADAL-ESTEROIDEA EN LOS MAMIFEROS QUE SUPONE LA REDUCCION DEL SUMINISTRO ESTROGENICO MEDIANTE LA ADMINISTRACION DE UN ANTAGONISTA GNRH EN CANTIDAD SUFICIENTE PARA EVITAR LA PROLIFERACION DE TEJIDO ENDOMETRIAL SIN DETENER BASICAMENTE LA PRODUCCION ENDOGENA DE ESTROGENOS. METODO PARA DETERMINAR SI EL SUMINISTRO REDUCIDO DES ESTROGENOS EN UN INDIVIDUO EN EL QUE SE HA SUPRIMIDO LA CONCENTRACION DE ESTRADIOL HASTA LLEGAR A UN NIVEL OPTIMIZADO APROPIADO PARA EL MANEJO TERAPEUTICO DE LA AFECCION DE CAUSA GONADAL-ESTEROIDEA, COMO PUEDE SER LA ENDOMETRIOSIS, EN ESE INDIVIDUO MEDIANTE LA ADMINISTRACION DE UN ANTAGONISTA GNRH A UN NIVEL DE DOSIFICACION DADO QUE IMPLICA EL AJUSTE DE LA DOSIS, P.E. MEDIANTE LA PUESTA EN PRACTICA DE UN TEST DE PRUEBA DE PROGESTERONA Y DOSIS DE REGIMEN OPTIMAS DE UN ANTAGONISTA GNRH.
ES95927228T 1994-07-22 1995-07-18 Uso de un antagonista gnrh para la preparacion de una composicion farmaceutica. Expired - Lifetime ES2145286T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (1)

Publication Number Publication Date
ES2145286T3 true ES2145286T3 (es) 2000-07-01

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95927228T Expired - Lifetime ES2145286T3 (es) 1994-07-22 1995-07-18 Uso de un antagonista gnrh para la preparacion de una composicion farmaceutica.

Country Status (29)

Country Link
EP (1) EP0769956B1 (es)
JP (1) JP3138477B2 (es)
CN (1) CN1137722C (es)
AP (1) AP775A (es)
AT (1) ATE190494T1 (es)
AU (1) AU691952B2 (es)
BG (1) BG63363B1 (es)
BR (1) BR9508718A (es)
CA (1) CA2195745C (es)
CY (1) CY2228B1 (es)
CZ (1) CZ291803B6 (es)
DE (1) DE69515666T2 (es)
DK (1) DK0769956T3 (es)
EE (1) EE03515B1 (es)
ES (1) ES2145286T3 (es)
FI (1) FI970244A (es)
GR (1) GR3033590T3 (es)
HU (1) HU218910B (es)
IL (1) IL114655A (es)
IS (1) IS4413A (es)
LV (1) LV11823B (es)
MX (1) MX9700574A (es)
NO (1) NO970257L (es)
NZ (1) NZ290554A (es)
OA (1) OA10730A (es)
PT (1) PT769956E (es)
RU (1) RU2181598C2 (es)
SK (1) SK282118B6 (es)
WO (1) WO1996003138A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
KR100772852B1 (ko) * 1999-09-23 2007-11-02 젠타리스 게엠베하 자궁내막증 치료용 약제학적 조성물
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
WO2009145690A1 (en) * 2008-05-29 2009-12-03 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
CZ15097A3 (en) 1997-11-12
PT769956E (pt) 2000-07-31
IL114655A0 (en) 1995-11-27
FI970244A0 (fi) 1997-01-21
ATE190494T1 (de) 2000-04-15
CZ291803B6 (cs) 2003-06-18
JP3138477B2 (ja) 2001-02-26
CN1200674A (zh) 1998-12-02
EP0769956A1 (en) 1997-05-02
EP0769956B1 (en) 2000-03-15
EE03515B1 (et) 2001-10-15
AU3132095A (en) 1996-02-22
LV11823B (en) 1998-03-20
DK0769956T3 (da) 2000-06-05
HU218910B (hu) 2000-12-28
NO970257D0 (no) 1997-01-21
BR9508718A (pt) 1997-12-30
AP9700913A0 (en) 1997-01-31
RU2181598C2 (ru) 2002-04-27
JPH10503203A (ja) 1998-03-24
CA2195745C (en) 2005-03-29
NZ290554A (en) 2000-08-25
IS4413A (is) 1997-01-14
BG63363B1 (bg) 2001-11-30
HUT77127A (hu) 1998-03-02
FI970244A (fi) 1997-01-21
SK7097A3 (en) 1997-11-05
WO1996003138A1 (en) 1996-02-08
DE69515666D1 (de) 2000-04-20
DE69515666T2 (de) 2000-07-06
CY2228B1 (en) 2003-04-18
HU9700046D0 (en) 1997-02-28
LV11823A (lv) 1997-08-20
BG101158A (en) 1997-09-30
AU691952B2 (en) 1998-05-28
MX9700574A (es) 1997-12-31
AP775A (en) 1999-10-28
NO970257L (no) 1997-01-21
EP0769956A4 (en) 1999-03-10
GR3033590T3 (en) 2000-09-29
SK282118B6 (sk) 2001-11-06
OA10730A (en) 2001-06-07
EE9700208A (et) 1998-02-16
IL114655A (en) 2005-08-31
CN1137722C (zh) 2004-02-11
CA2195745A1 (en) 1996-02-08

Similar Documents

Publication Publication Date Title
ES2132645T3 (es) Uso en una composicion farmaceutica.
ES2145286T3 (es) Uso de un antagonista gnrh para la preparacion de una composicion farmaceutica.
DK0799043T3 (da) Cyklofasisk hormonel kur indeholdende antiprogestin og progestin
NO20051545L (no) Ostrogenerstatningsregime
MX2022000279A (es) Regimenes de antagonistas del receptor de estrogeno.
ECSP055574A (es) Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.
MX2007006063A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central.
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
PA8578001A1 (es) Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
AR023510A1 (es) Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
Razzaghdoust et al. Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
CY1108648T1 (el) Αναστολεας της αρωματασης σε μια δοση για την θεραπευτικη αντιμετωπιση της υπογόνιμοτήτας
JO1879B1 (en) Consolidation of the secretion of ovarian estrogen for prolonged treatment regimens
MX9300406A (es) Derivados azabiciclicos procedimientos para su preparacion y composiciones que los contienen.
AR044450A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
ES2173294T3 (es) Nuevo uso medico.
AR116592A1 (es) Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
MX2022012259A (es) Compuestos activos frente a receptores nucleares.
AR126766A1 (es) Método para tratar endometriosis y proporcionar una anticoncepción eficaz
UY31306A1 (es) Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapéuticos, asi como reduccion del riesgo de malformaciones congénitas al comenzar un embarazo
CO2022016665A2 (es) Composiciones y métodos para suministrar agentes farmacéuticamente activos
UY26539A1 (es) Drospirenona para terapia de reemplazo de hormonas.
CH534124A (de) Verfahren zur Herstellung von tricyclischen Aminen
Fraschini Role of indoleamines in the control of the secretion of pituitary gonadotropins

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 769956

Country of ref document: ES